53385-82-3

Upstream product

• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 103-72-0 phenyl isothiocyanate 

Downstream Products

• 131185-00-7 N-(5-methylpyridin-2-yl)thiourea 
• 1266676-94-1 2-(5-methylpyridin-2-ylamino)-thiazole-4-carboxylic acid (3,4-dimethoxyphenyl)-amide 
• 1266676-76-9 [4-(5-methyl-3-phenylisoxazol-4-yl)-thiazol-2-yl]-(5-methylpyridin-2-yl)-amine 
• 1266676-75-8 (5-methylpyridin-2-yl)-[4-(3-phenylisoxazol-5-yl)-thiazol-2-yl]-amine 
• 709001-36-5 (5-methylpyridin-2-yl)-(4-phenylthiazol-2-yl)-amine 
• 1266676-73-6 [4-(2-methoxyphenyl)-thiazol-2-yl]-(5-methylpyridin-2-yl)-amine 
• 708999-56-8 [4-(4-methoxyphenyl)-thiazol-2-yl]-(5-methylpyridin-2-yl)-amine 
• 757195-97-4 [4-(3,4-dimethoxyphenyl)-thiazol-2-yl]-(5-methylpyridin-2-yl)-amine 
• 117636-09-6 Cu(bis{N-2-⁽⁵⁾picolyl-N'-(phenyl)thiourea})⁽²⁺⁾ 

Relevant academic research and scientific papers

Structural, spectral and thermal studies of substituted N-(2-pyridyl)-N′-phenylthioureas

N-2-(3-picolyl)-N′-phenylthiourea, 3PicTuPh, monoclinic, P21/n, a = 7.617(2) b = 7.197(5), c = 22.889(5) ?, β = 94.63(4)°, V = 1250.7(1) ?3 and Z = 4; N-2-(4-picolyl)-N′-phenylthiourea, 4PicTuPh, triclinic, P-1, a = 7.3960(5), b = 7.

2-aminothiazoles as therapeutic leads for prion diseases

2-Aminothiazoles are a new class of small molecules with antiprion activity in prion-infected neuroblastoma cell lines (J. Virol. 2010, 84, 3408). We report here structure-activity studies undertaken to improve the potency and physiochemical properties of 2-aminothiazoles, with a particular emphasis on achieving and sustaining high drug concentrations in the brain. The results of this effort include the generation of informative structure-activity relationships (SAR) and the identification of lead compounds that are orally absorbed and achieve high brain concentrations in animals. The new aminothiazole analogue (5-methylpyridin-2-yl)-[4-(3-phenylisoxazol-5-yl)-thiazol-2-yl]-amine (27), for example, exhibited an EC50 of 0.94 μM in prion-infected neuroblastoma cells (ScN2a-cl3) and reached a concentration of ～25 μM in the brains of mice following three days of oral administration in a rodent liquid diet. The studies described herein suggest 2-aminothiazoles as promising new leads in the search for effective therapeutics for prion diseases.